ElevateBio Unveils Promising Gene Editing Data for Huntington’s Disease

ElevateBio has announced promising new preclinical data for LETI-101, its investigational gene-editing therapy for Huntington’s disease (HD). The therapy utilizes a proprietary CRISPR-based approach to selectively target the mutant huntingtin (mHTT) protein, while preserving the healthy form necessary for cellular function. In studies, LETI-101 demonstrated an impressive reduction of mHTT levels—exceeding 80%—in a widely recognized HD transgenic mouse model. The treatment also showed strong safety signals in nonhuman primate studies, with no observed adverse effects at the highest tested dose. These findings will be presented at the 20th Annual Huntington's Disease Therapeutics Conference.

David Hallal, Chairman and CEO of ElevateBio, emphasized the significance of these results, highlighting the company’s unique combination of gene-editing expertise and advanced manufacturing capabilities. "The progress of LETI-101 is a testament to our ability to integrate cutting-edge technology with scalable manufacturing to drive innovation in genetic medicine," he said. With regulatory alignment from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), ElevateBio is now exploring partnership opportunities to accelerate the therapy’s path toward clinical trials, offering renewed hope for patients and families affected by this devastating disease.